Allogenic cell secretions - Cambium Bio
Alternative Names: MSC derived secretome - Cambium Bio; MSC- derived bioactive secretome - Cambium Bio; Secretome - Cambium Bio; SygenusLatest Information Update: 28 Aug 2025
At a glance
- Originator Regeneus ltd
- Developer Cambium Bio
- Class Analgesics; Anti-inflammatories; Antiacnes; Proteins; Skin disorder therapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Acne; Lichen planus; Neuropathic pain; Wounds
Most Recent Events
- 28 Aug 2025 No recent reports of development identified for preclinical development in Wounds in Australia (Topical, Gel)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Lichen-planus in Australia (Topical, Gel)
- 28 Jul 2025 No recent reports of development identified for preclinical development in Neuropathic-pain in Australia (Topical, Gel)